Adaptimmune Therapeutics (ADAP) Reports In-Line Q3 EPS

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $40.9 million versus the consensus estimate of $18.57 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Morgan Stanley Downgrades Peloton Interactive (PTON) to Underweight
• JPMorgan Downgrades Societe Generale SA (GLE:FP) (SCGLY) to Neutral
• Jefferies Upgrades DWS Group GmbH & Co KGaA (DWS:GR) to Buy